Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis through Inactivation of P300 Signaling by Xiao, Xiangsheng et al.
Quercetin Suppresses Cyclooxygenase-2 Expression and
Angiogenesis through Inactivation of P300 Signaling
Xiangsheng Xiao
1., Dingbo Shi
1., Liqun Liu
2., Jingshu Wang
1., Xiaoming Xie
1, Tiebang Kang
1, Wuguo
Deng
1*
1State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China, 2The First Affiliated Hospital-Huangpu Hospital, Sun Yat-
Sen University, Guangzhou, China
Abstract
Quercetin, a polyphenolic bioflavonoid, possesses multiple pharmacological actions including anti-inflammatory and
antitumor properties. However, the precise action mechanisms of quercetin remain unclear. Here, we reported the
regulatory actions of quercetin on cyclooxygenase-2 (COX-2), an important mediator in inflammation and tumor promotion,
and revealed the underlying mechanisms. Quercetin significantly suppressed COX-2 mRNA and protein expression and
prostaglandin (PG) E(2) production, as well as COX-2 promoter activation in breast cancer cells. Quercetin also significantly
inhibited COX-2-mediated angiogenesis in human endothelial cells in a dose-dependent manner. The in vitro streptavidin-
agarose pulldown assay and in vivo chromatin immunoprecipitation assay showed that quercetin considerably inhibited the
binding of the transactivators CREB2, C-Jun, C/EBPb and NF-kB and blocked the recruitment of the coactivator p300 to COX-
2 promoter. Moreover, quercetin effectively inhibited p300 histone acetyltransferase (HAT) activity, thereby attenuating the
p300-mediated acetylation of NF-kB. Treatment of cells with p300 HAT inhibitor roscovitine was as effective as quercetin at
inhibiting p300 HAT activity. Addition of quercetin to roscovitine-treated cells did not change the roscovitine-induced
inhibition of p300 HAT activity. Conversely, gene delivery of constitutively active p300 significantly reversed the quercetin-
mediated inhibition of endogenous HAT activity. These results indicate that quercetin suppresses COX-2 expression by
inhibiting the p300 signaling and blocking the binding of multiple transactivators to COX-2 promoter. Our findings
therefore reveal a novel mechanism of action of quercetin and suggest a potential use for quercetin in the treatment of
COX-2-mediated diseases such as breast cancers.
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Introduction
Quercetin is a dietary polyphenolic flavonoid found in many
fruits, vegetables, nuts, and red wine, and exerts diverse biological
activities including anti-inflammatory and antitumor properties
[1–6]. It possesses chemotherapeutic potential in various cancers,
and be capable of modulating several signal transduction pathways
associated with cell survival, proliferation and apoptosis [7–20].
Previous study has shown that quercetin inhibits tumor necrosis
factor-a (TNF)-induced NF-kB transcription factor recruitment to
proinflammatory gene promoters in the murine small intestinal
epithelial cells [6]. Quercetin inhibited TNF-induced interferon-d-
inducible protein 10 (IP-10) and macrophage inflammatory
protein 2 (MIP-2) gene expression by inhibiting histone acetyl-
transferase (HAT) activity and histone 3 (H3) acetylation/
phosphorylation as well as blocking phospho-Rel A (NF-kB p65)
and cofactor CBP/p300 binding to the IP-10 and MIP-2 gene
promoters. These studies support an anti-inflammatory effect of
quercetin in epithelial cells through mechanisms that inhibit NF-
kB and cofactor recruitment at the chromatin of proinflammatory
genes.
Cyclooxygenase-2 (COX-2) is an inducible enzyme which plays
a critical role in multiple pathophysiological processes including
inflammation, atherosclerosis, tissue injury, angiogenesis and
tumorigenesis [21–24]. COX-2 catalyzes the conversion of
arachidonic acid to prostaglandin H2, which is further converted
to biologically active prostaglandins and thromboxane A2 (TXA2)
by specific enzymes [25–27]. Abnormal expression of cyclooxy-
genase-2 (COX-2) is an important mediator in inflammation and
tumor promotion. It has been shown that overexpression of COX-
2 is significantly correlated to invasiveness, prognosis, and survival
in some cancers [28–30]. Inhibition of COX-2 with selective
COX-2 inhibitors effectively prevents inflammation, proliferation
and angiogenesis, and induces apoptosis in human cells.
Importantly, COX-2 inhibitors have been shown to act additively
or synergistically with currently used chemotherapeutic and
targeted agents [31–33].
COX-2 transcriptional regulation has been extensively charac-
terized. A core promoter region within 500 bp from the COX-2
transcription start site harbors several regulatory elements notably
cyclic AMP response element (CRE), CCAAT/enhancer binding
protein (C/EBP) enhancer element and NF-kB binding sites, that
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inflammatory signals [34,35] . Binding of multiple transactivators
to their respective cis-acting elements on the core COX-2
promoter results in overexpression of COX-2. Importantly, p300
has been shown to exert a global effect on COX-2 promoter
chromatin structure, which is able to enhance the binding of
transactivators to COX-2 promoter. The mechanism by which
COX-2 is highly expressed in tumorigenesis and angiogenesis is
not completely understood.
COX-2 expression is reported to be abrogated by an array of
small-molecule compounds such as melatonin and salicylate
[36,37]. Numerous studies have also demonstrated the inhibitory
effects of quercetin on COX-2 expression [38–40]. Although
quercetin has been shown to inhibit TNF-induced expression of
the proinflammatory genes IP-10 and MIP-2 by targeting the NF-
kB signaling pathway and modulating H3 acetylation in murine
small intestinal epithelial cells [6], the excise molecular mecha-
nisms by which quercetin inhibits expression of the specific
proinflammatory gene such as COX-2 in human cancer cells
remained unclear.
In this study, we investigated the mechanisms of action of
quercetin for COX-2 suppression in human breast cancer cells
and demonstrated that quercetin specifically targeted at p300
signaling pathway to regulate COX-2 expression and COX-2-
mediated angiogenesis. We found that quercetin suppressed p300
HAT activity, abolished the p300-mediated NF-kB p50 acetyla-
tion, and blocked binding of p300 and the multiple transactivators
such as CREB2, C-Jun, C/EBPb and NF-kB to COX-2 gene
promoter in human breast cancer cells. Our study therefore
reveals a novel molecular mechanism by which quercetin inhibits
COX-2 expression in human cancer cells and suggests a potential
use for quercetin in the treatment of COX-2-mediated diseases
such as breast cancers.
Results
Quercetin suppressed COX-2 expression and PGE2
production
Abnormal expression of COX-2 is an important mediator in
tumor promotion. To determine whether quercetin regulated
COX-2 expression in breast cancer cells, we evaluated the effect of
quercetin on COX-2 protein and mRNA levels by Western blot
and RT-PCR, respectively. We detected high expression of COX-
2 protein (Figure 1A) and mRNA (Figure 1B) in breast cancer
MDA-MB-2321 cells. Treatment of quercetin inhibited COX-2
protein expression in a concentration-dependent manner
(Figure 1A). Similarly, quercetin also suppressed COX-2 mRNA
levels to a similar extent in MDA-MB-231 cells (Figure 1B).
PGE2 is a downstream product of COX-2, and it is synthesized
via the cyclooxygenase and prostaglandin synthase pathways. We
also evaluated the effect of quercetin on PGE2 production. In
accordance with inhibition of COX-2 expression, quercetin
reduced PGE2 production in a comparable dose-dependent
manner in MDA-MB-231 cells (Figure 1C).
Quercetin inhibited COX-2 promoter activation
To determine whether quercetin also suppressed COX-2
transcription activation in breast cancer cells, we next determined
the effects of quercetin on COX-2 promoter activity. We
transfected MDA-MB-231 and MCF7 cells with a luciferase
expression vector containing a 900 bp (2891/+9) COX-2 5-
flanking fragment or its different deletion mutants (Figure 2A).
The results showed that the promoter activity was comparably
inhibited by quercetin in MDA-MB-231 cells (Figure 2B), parallel
to that of COX-2 protein and mRNA suppression (Figure 1A, 1B).
Treatment with quercetin dose-dependently suppressed COX-2
promoter activity in all MDA-MB-231 cells transfected with
different vectors containing a 900-bp COX-2 promoter region or
its deletion mutants except for the shortest mutant (296/+9)
(Figure 1B). Similarly, quercetin also significantly inhibited COX-
2 promoter activity in a dose-dependent manner in MCF7 cells
transfected with the vectors containing a 900-bp COX-2 promoter
region (2891/+9) or its deletion mutant (2361/+9) (Figure 2C).
Quercetin inhibited angiogenesis
COX-2 expression and PGE2 production have been shown to
induce angiogenesis, cell proliferation and invasion. We next
determined the effects of quercetin on COX-2-induced angiogen-
esis in human endothelial cell line HUVECs by analyzing
endothelial tube formation. VEGF165 induced COX-2 expression
at mRNA (Figure 3A) and protein (Figure 3B) levels in HUVECs.
Figure 1. Quercetin suppressed COX-2 expression and PGE2
production. Human MDA-MB-231 cells were treated with quercetin for
48 h. The COX-2 proteins (A) and mRNA (B) were analyzed by Western
blotting and RT-PCR, respectively, and PGE2 in medium of MDA-MB-231
cells was tested by ELISA (C). b-Actin and GAPDH were used as controls
for sample loading. This is a representative of three blots. Each bar
denotes mean 6 SD of three experiments. *, P,0.05, significant
differences between treatment groups and control groups.
doi:10.1371/journal.pone.0022934.g001
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enhanced by addition of exogenous VEGF165 (Fig. 3C). Quercetin
suppressed expression of COX-2 mRNA (Figure 3A) and protein
(Figure 3B) in HUVECs induced by VEGF165. Furthermore,
quercetin significantly inhibited VEGF165-induced tube formation
in a dose-dependent manner (Figure 3C).
DLD-1 colon cancer cells have been reported to produce
angiogenic factors and co-culture of these cells with endothelial
cells stimulates tube formation. We next examined whether the
conditioned medium (CM) from the colon cancer cells had an
effect on tube formation and whether quercetin inhibited the tube
formation. We washed DLD-1 cells and incubated them in serum-
free medium for 24 h. The conditioned medium (CM) was
collected and added to HUVECs seeded on growth factor-reduced
Matrigel. As shown in Figure 3D, the DLD-1 conditioned medium
(CM) induced tube formation by comparison with the basal
control, and pretreatment with quercetin significantly suppressed
endothelial tube formation in a concentration-dependent manner.
Quercetin suppressed CREB-2, c-Fos, C/EBPb, NF-kB and
p300 binding to COX-2 promoter probe
The transcription activation of genes is regulated by the binding
activities of transactivators and coactivators on gene promoter
structure. Previous study has shown that quercetin suppressed
expression of the proinflammatory genes IP-10 and MIP-2 by
inhibiting TNF-induced phospho-RelA (NF-kB p65) and cofactor
CBP/p300 recruitment to the IP-10 and MIP-2 promoters in the
murine small intestinal epithelial cells [6]. To determine whether
the quercetin-induced suppression of COX-2 expression is
mediated by inhibition of the binding of the functionally important
transactivators to COX-2 promoter in human breast cancer cells,
we tested the effect of quercetin on the binding activities of CREB-
2, C-Fos, C/EBPb, NF-kB p65, and NF-kB p50 to the COX-2
promoter in MDA-MB-231 cells. We used a biotin-labeled 479-bp
COX-2 promoter region corresponding to the 5- flanking
sequence of human COX-2 gene from 230 to 2508 as the
probe to assess the binding of transactivators to COX-2 promoter
by a streptavidin-agarose pulldown assay (Figure 4A). Nuclear
extracts prepared from the quercetin-treated cells were incubated
with a biotin-labeled COX-2 promoter probe and streptavidin-
conjugated agarose beads. The biotin-streptavidin complex was
pulled down and transactivators in the pulldown complex were
analyzed by Western blotting. We chose to analyze the
transactivators CREB-2, C-Fos, C/EBPb and NF-kB as their
binding to COX-2 promoter has been shown to be regulated. The
results showed that quercetin dramatically inhibited the binding of
muliple transactivators (CREB-2, c-Fos, C/EBPb, and NF-kB
p50, NF-kB p65) to the COX-2 promoter probe in human breast
cancer MDA-MB-231 cells (Figure 4B). By contrast, treatment of
quercetin did not change the expression levels of all transactivators
(Figure 4B).
P300 is a transcription co-activator that integrates the
transcriptional signal by interacting with promoter-bound
transactivators such as CREB, C/EBPb, C-Jun and NF-kB
(34). Since quercetin inhibited binding of transactivators to COX-
2 promoter, we suspected a consequent reduction in the level of
p300 in the DNA-transactivator complex. The streptavidin-
agarose bead pulldown assay showed that quercetin inhibited
p300 recruitment to the transactivators-COX-2 promoter
complex in MDA-MB-231 cells (Figure 4B). Quercetin did not
change p300 protein expression levels (Figure 4B). These results
suggest that COX-2 suppression is mediated by inhibiting
transactivator binding and p300 recruitment to COX-2 promoter
in MDA-MB-231 cells.
We also detected the effect of quercetin on binding activities of
two key transactivators NF-kB p50 and NF-kB p65 in MCF7
breast cancer cells. Consistent with the data from MDA-MB-231
cells, treatment of MCF7 cells with quercetin also effectively
inhibited p50 and p65 binding to COX-2 promoter probe, but did
not change the total protein levels (Figure 4D).
Quercetin inhibited CREB-2, c-Fos, C/EBPb, NF-kB and
p300 recruitment to chromatin COX-2 promoter region
To confirm the inhibitory effect of quercetin on transactivator
binding and p300 recruitment in vivo, we performed chromatin
immunoprecipitation (ChIP) using antibodies directed at CREB-2,
c-Fos, C/EBPb, NF-kB p65, NF-kB p50, and p300 to precipitate
chromatin. The cells were treated with quercetin for 48 h and the
Figure 2. Quercetin inhibited COX-2 promoter activity. MDA-
MB-231 and MCF7 cells were transfected with a luciferase expression
vector containing a 900-bp wild-type COX-2 promoter or its 5-deletion
mutants (A), and then treated with quercetin for 24 h. Luciferase
activity was measured using a luminometer and the results were
expressed as relative light unit (RLU) (B, C). Numbers shown for each
promoter construct correspond to the COX-2 promoter sequence. Each
bar denotes mean 6 SD of three experiments. *, P,0.05, significant
differences between treatment groups and control groups.
doi:10.1371/journal.pone.0022934.g002
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amplified by PCR. As shown in Figure 4C, quercetin significantly
inhibited binding of CREB-2, c-Fos, C/EBPb, NF-kB p50, NF-kB
p65, and p300 to chromatin COX-2 promoter in MDA-MB-231
cells. Similarly, quercetin also effectively blocked the binding of
transactivators p50 and p65 to chromatin COX-2 promoter in
MCF7 cells (Figure 4E). These results are in agreement with those
obtained from the in vitro DNA-binding assays (Figure 4B and 4D).
Figure 3. Quercetin inhibited endothelial tube formation. The HUVEC cells were plated in six-well plates pre-coated with growth factor-
reduced Matrigel and treated with quercetin together with VEGF165 (10 ng/ml) or DLD-1 cancer cell medium and incubated at 37uC for 4 h and 24 h.
COX-2 mRNA (A) and protein (B) were analyzed by RT-PCR and Western blotting, respectively. HUVEC tube formation was counted by phase-contrast
photographs. Mean values of tube formation on growth factor-rich Matrigel induced by VEGF165 (C) and DLD-1 conditioned medium (D) were
calculated from three separate experiments. The data are presented as mean 6 SD of three separate experiments. *, P,0.05, significant differences
between treatment groups and control groups. C, PCR control; Basal, medium-treated cells as negative control.
doi:10.1371/journal.pone.0022934.g003
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Quercetin has been shown to inhibit total HAT activity in
murine small intestinal epithelial cells [6]. As quercetin exerts a
global effect on transactivator binding and p300 recruitment to
COX-2 promoter, we determined whether p300 HAT might be
a target of transcriptional control by quercetin in human breast
cancer cells and evaluated the effect of quercetin on p300 HAT
activity in the p300-overexpressed breast cancer cells. We
transfected MDA-MB-231 and MCF7 cells with a FLAG-p300
vector for 24 h, and then treated the p300-transfected cells with
quercetin for 24 h. Nuclear extracts were immunoprecipitated
with a FLAG antibody, and the overexpressed FLAG-p300 in
the precipitates was eluted using FLAG peptides. HAT activity
of the purified p300 was determined. Our results showed that
quercetin significantly inhibited p300 HAT activity in vivo in a
concentration-dependent manner in human breast cancer in
human breast cell lines (Figure 5A).
We also determined whether quercetin directly inhibited p300
HAT activity in vitro. The MDA-MB-231 cells were transfected
with FLAG-p300 vectors for 48 h and FLAG-p300 proteins were
isolated. The purified p300 proteins were treated with quercetin
and HAT activity of the purified p300 was analyzed. Quercetin
Figure 4. Quercetin inhibited binding of multiple transactivators and p300 to COX-2 promoter. Human MDA-MB-231 and MCF7 cells
were treated with quercetin for 48 h. The binding of transactivators and p300 to COX-2 promoter was analyzed by streptavidin-agrose pulldown
assay or ChIP assay. A biotin-labeled COX-2 promoter probe (A) which harbors all the indicated transactivators was used. Nuclear proteins in MDA-
MB-231 (B) and MCF7 (D) cells were incubated with the COX-2 probe and streptavidin-agrose beads. After centrifugation, proteins in the complex
were detected by immunoblots (B, D). Chromatin in MDA-MB-231 (C) and MCF7 (E) cells was immunoprecipitated with antibodies to the indicated
transactivators and the COX-2 promoter region in the precipitated chromatin was amplified by PCR. The non-immuno IgG was used as negative
control. The figures are representative of three experiments. IgG, non-immuno IgG.
doi:10.1371/journal.pone.0022934.g004
Quercetin Suppresses Cyclooxygenase-2 Expression
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e22934also significantly inhibited p300 HAT activity in vitro in human
breast cell lines (Figure 5B), which is comparable to its inhibition
of p300 HAT in vivo (Figure 5A).
Quercetin attenuatedp300-mediatedacetylationof NF-kB
Previous study demonstrated that quercetin inhibited TNF-
induced acetylation/phosphorylation of histone (H3) in murine
small intestinal epithelial cells [6]. The NF-kB p50 has been shown
to be acetylated by p300 HAT. To further confirm the quercetin-
mediated suppression of p300 HAT in human breast cancer cells,
we evaluated the effect of quercetin on NF-kB acetylation in p300-
tranfected MDA-MB-231 cells. The results showed that quercetin
significantly inhibited the p300 HAT-mediated acetylation of NF-
kB p50, resulting in a marked reduction in acetyl-p50 protein
levels. By contrast, quercetin did not change the levels of total p50
proteins in p300-tranfected MDA-MB-231 cells (Figure 6A).
Streptavidin-agarose pulldown and ChIP assay also showed that
quercetin dramatically suppressed binding of p50 to the
biotinylated COX-2 promoter probe (Figure 6B) and the
chromatin COX-2 promoter region (Figure 6C) in p300-
tranfected MDA-MB-231 cells.
To confirm the inhibition of p300 signaling by quercetin, we
treated MDA-MB-231 cells with the p300 inhibitor roscovitine
Figure 5. Quercetin suppressed p300 HAT activity. (A), Human
MDA-MB-231 and MCF7 cells were transfected with FLAG-p300 for 24 h
and then treated with quercetin for 24 h. The p300 protein was isolated
from nuclear extracts and HAT activity was measured. (B), MDA-MB-231
cells were transfected with FLAG-p300. The p300 protein was isolated
from nuclear extracts and then treated with quercetin in vitro for
30 min. HAT activity was measured. Each bar represents mean 6SD of
three experiments. *, P,0.05, significant differences between treatment
groups and control groups.
doi:10.1371/journal.pone.0022934.g005
Figure 6. Quercetin inhibited NF-kB acetylation. (A–C), The MDA-
MB-231 cells were transfected with FLAG-p300 for 24 h and then treated
with quercetin for 24 h. Nuclear extracts were prepared and p50 was
immunoprecipitated with a p50 antibody. Acetylated p50 (Actyl-p50) (A)
was analyzed by Western blots using an acetyl-lysine antibody. The
binding of p50 to a biotinylated COX-2 promoter probe (B) and
chromatin structure (C) were detected by streptavidin-agarose pulldown
and ChIP assay, respectively. (D), MDA-MB-231 cells were treated with
roscovitine (20 mM) or quercetin (100 mM) for 24 h, then transfected with
p300-expressing vector. After 24 h, the HAT activity was measured. The
empty vector was used as a transfection control. The figures are
representatives of three experiments. Each bar represents mean 6SD of
three experiments. *, P,0.05, significant differences between treatment
groups and control groups. NSP, non-specific probe; EV, empty vector.
doi:10.1371/journal.pone.0022934.g006
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their effects on p300 HAT inhibition. As shown in Figure 6D,
roscovitine was as effective as quercetin at inhibiting p300 HAT
activity. Addition of quercetin to the roscovitine-treated cells did
not change the inhibition of p300 HAT mediated by roscovitin
(Figure 6D). However, transfection of p300 expressing vector in
the quercetin-pretreated cells significantly reversed inhibition of
the endogenous HAT activity mediated by quercetin (Figure 6D).
Taken together, these results indicate that p300 HAT is an
important target of transcriptional control by quercetin. Quercetin
directly inhibits p300 HAT, thereby attenuating the acetylation
and binding of transactivators and suppressing the expression of
COX-2.
Discussion
In this study, we evaluated the response of human breast cancer
cells to quercetin treatment. Our results showed that quercetin
significantly suppressed COX-2 expression and PGE2 production,
as well as COX-2 promoter activation. We also found that
quercetin significantly inhibited angiogenesis by suppressing
endothelial tube formation in human HUVEC cells. Furthermore,
mechanic study showed that suppression of COX-2 expression by
quercetin is mediated mainly by inhibiting p300 HAT activity,
thereby attenuating the acetylation of transactivators and their
binding to COX-2 promoter. Our results indicate that quercetin
may target the p300 signaling to inhibit COX-2 expression in
human breast cancer cells.
Quercetin has been shown to inhibit TNF-induced expression
of the proinflammatory genes IP-10 and MIP-2 by modulating
TNF-induced NF-kB signaling in murine intestinal epithelial cells
(IECs) [6]. Quercetin reduces total HAT activity, blocks TNF-
induced acetylation and/or phosphorylation of histone 3 (H3), and
inhibits the recruitment of the NF-kB cofactor CBP/p300 to the
IP-10 and MIP-2 gene promoters. These results suggest that
quercetin may target the TNF-induced transcriptional regulation
at the chromatin. However, whether quercetin may specifically
target p300 signaling pathway to regulate expression of the
inflammation and cancer-related genes remains unknown.
COX-2 is a specific proinflammatory gene. Excessive COX-2
expression plays a key role in inflammatory disorders and cancers.
In this study, we revealed the molecular mechanisms by which
quercetin inhibited COX-2 expression and COX-2-mediated
angiogenesis in human breast cancer cell lines. Unlike the
quercetin-mediated regulation of IP-10 and MIP-2 gene expres-
sion in murine intestinal epithelial cells, our results showed that
quercetin suppressed COX-2 expression in human breast cancer
cells by specifically targeting the p300 signaling pathway. We
found that quercetin specifically inhibited p300 HAT activity in
vitro and in vivo, blocked p300 HAT-mediated acetylation of NF-kB
p50, and inhibited the binding of p300 to COX-2 promoter probe
in vitro and to chromatin COX-2 promoter region in vivo in human
breast cells. Interestingly, and most important for understanding
the mechanism involved, quercetin dramatically inhibited the
recruitment of multiple transactivators such as CREB-2, c-Fos, C/
EBPb, NF-kB to COX-2 promoter, suggesting that quercetin may
target the p300 signaling and modulate the binding activities of the
functionally important transactivators at the promoter to regulate
COX-2 transcriptional activation. To our knowledge, this is an
important finding that demonstrated suppression of p300 signaling
by quercetin in human breast cancer cells.
COX-2 expression and PGE2 production have been shown to
upregulate the EGFR, PI3k and Erk1/2 signaling, thereby
inducing angiogenesis, cell proliferation and invasion. COX-2
inhibition may result in cell growth suppression and apoptosis
induction. The AMP kinase/cyclooxygenase-2 signaling pathway
has been shown to regulate proliferation and apoptosis of cancer
cells treated with quercetin and is important in quercetin-mediated
cancer control. Quercetin activates AMP-activated protein kinase
(AMPK) and inhibits cyclooxygenase (COX-2) expression in
breast and colon cancer cell lines [13].
COX-2 promoter activation is mediated by binding of multiple
transactivators to enhancer elements of COX-2 promoter. Results
from previous studies show that the CRE site, C/EBP site, and
two kB sites are essential for COX-2 promoter activity [34,35]. It
has been shown that CREB-2 and AP-1 (c-Jun and c-Fos) bind to
the CRE and its surrounding region, C/EBPb binds to the C/EBP
site, and NF-kB binds to both kB sites. We designed a COX-2
promoter region that includes all four binding sites as a probe to
study the effects of quercetin on COX-2 transcription activation.
We demonstrated the inhibitory effects of quercetin on the binding
of transactivators CREB-2, c-Fos, C/EBPb and NF-kB to COX-2
promoter in vitro by streptavidin-agarose pulldown. We also
showed by in vivo ChIP assay that quercetin suppressed binding
of transactivators to chromatin COX-2 promoter structure. The
transactivators recruit p300 coactivator to COX-2 promoter
where the coactivators interact with the transcriptional machinery
and thereby integrate the signal for promoter activation. We
provide evidence in this study that quercetin also inhibited p300
recruitment to the COX-2 promoter. Taken together, our data
suggest that quercetin inhibits COX-2 expression in breast cancer
cells by suppressing transactivator DNA binding activities, thereby
compromising p300 recruitment and resulting in suppression of
COX-2 promoter activity. The mechanisms by which quercetin
blocks transactivator binding remain to be unclear. Previous study
showed quercetin inhibited TNF-induced NF-kB transcription
factor recruitment to proinflammatory gene promoters in murine
intestinal epithelial cells [6]. As the DNA binding activities of
transactivators such as AP-1, C/EBPb and NF-kB are regulated
by phosphorylation via multiple kinase signaling pathways [41], it
is possible that quercetin may suppress transactivator binding by
inhibiting a common kinase pathway.
P300 is expressed in abundance in cancer cells and p300
overexpression augments COX-2 transcriptional activation in-
duced by diverse pro-inflammatory mediators [35]. It serves as a
transcription coactivator to bridge the promoter-bound transacti-
vators with transcriptional factors in the transcription machinery.
P300 HAT acetylates histones thereby opening the chromatin
structure and increasing access of enhancer elements to transacti-
vators. P300 HAT is also capable of acetylating transactivators
such as NF-kB, thereby enhancing transactivator binding [34,35].
P300 HAT has been shown to be essential for COX-2 promoter
activation. The p300 HAT deletion or HAT inhibitors abrogate
the stimulatory effect of diverse pro-inflammatory mediators on
COX-2 expression [34,35]. Importantly, p300 HAT exerts a
global effect on COX-2 promoter chromatin structure to enhance
binding of transactivators. Consistent with the previous reports,
our present study have also showed that p300 HAT plays a crucial
role in regulating COX-2 expression. We found that quercetin
suppresses COX-2 expression mainly by inhibiting p300-mediated
acetylation of transactivators in human breast cancer cells.
However, the role of quercetin in regulating histone acetylation
on COX-2 promoter remains unclear and further studies are
needed.
That quercetin inhibits p300 HAT activity suggests that
quercetin targets at p300 HAT, thereby blocking the access of
transactivators and p300 to the COX-2 promoter region.
Quercetin may inhibit the catalytic center of p300 HAT. It also
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tion. It has been shown that p300 HAT is regulated by p300
phosphorylation or acetylation [42,43]. It is possible that quercetin
suppresses p300 phosphorylation, alters p300 HAT conformation
and catalytic activity, and inhibits the post translational modifi-
cation of p300 HAT, thereby blocking HAT activity in breast
cancer cells. Previous study also showed that histone acetylation by
p300 is involved in CREB-mediated transcription on chromatin
[43]. Further studies are needed to elucidate the mechanism by
which quercetin inhibits p300 HAT activity.
The transcriptional control by quercetin in breast cancer cells is
likely not limited to COX-2 gene but also other genes, especially the
pro-inflammatory, mitogenic and oxygenases whose promoter
activities are regulated by p300 HAT and whose overexpression
cause oxidative DNA damage and the consequent mutation and
cellular changes. Our results should light on an important
transcriptional control program mediated by quercetin in breast
cancer cells.Our findings provide new insights intounderstanding the
molecular mechanisms of quercetin-mediated tumor suppression and
suggest that flavonoids such as quercetin may be effective agents for
the treatment of COX-2-medaited human diseases such as cancers.
Materials and Methods
Cell lines and cell culture
Human breast cancer cells MDA-MB-231, MCF7 and colon
cancer cells DLD-1, and primary human umbilical vein
endothelial cells (HUVECs) were obtained from American Type
Culture Collection (ATCC, Manassas, VA). The MDA-MD-231
and DLD-1 cells were cultured in RPMI1640 medium (Invitrogen,
Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS)
(HyClone, Logan, UT), 5% glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin (Invitrogen, Carlsbad, CA). The primary
HUVECs were maintained in medium M199 (Life Technologies,
Gaithersburg, MD) containing 4 mM L-glutamine, 90 mg/ml
heparin, 1 mM sodium pyruvate, 30 mg/ml endothelial cell
growth stimulant (Biomedical Products, Bedford, MA), and 20%
FBS (HyClone, Logan, UT). Only cells at passage 2 to 4 were used
in our experiments. All cell lines were grown at 37uCi na n
atmosphere of 5% CO2. In all experiments, 80–90% of confluent
cells were washed and incubated in serum-free medium for 24 h
prior to treatment with quercetin (Sigma, St. Louis, MO) or
PD098059 (Cell Signaling Technology, Beverly, MA) for 48 h.
Western blot analysis
Cell lysate proteins were separated by electrophoresis in a 4–
15% sodium dodecyl suplhaste-polyacrylamide gradient minigel
(SDS-PAGE) (Bio-Rad, Hercules, CA) and electrophoretically
transferred to a nitrocellulose membrane (Amersham Pharmacia
Biotech, Piscataway, NJ). Western blots were probed with
antibodies against COX-2, CREB2, C-Jun, C/EBPb, p50, p65,
p300 (Santa Cruz Biotechnology, Santa Cruz, CA). The protein
bands were detected by enhanced chemiluminescence (Amersham
Pharmacia Biotech, Piscataway, NJ).
RT-PCR
Total RNA was extracted with Tri-Zol reagent (Life Technol-
ogies, Glasgow, UK) according to the manufacturer’s instructions.
cDNA was synthesized and used for amplification of COX-2 gene.
The amplified products were visualized on 1% agarose gels.
PGE2 assay
Amounts of PGE2 in the conditioned media collected from the
quercetin-treated cells were determined by an enzyme-linked
immunosorbent assay according to the instructions of the
manufacturer (Amersham Pharmacia Biotech, Piscataway, NJ).
Analysis of promoter activity
A promoter region of human COX-2 gene (2891 to +9) and its
fragment deletions (Figure 2D) were constructed into a luciferase
reporter vector pGL3. The COX-2 promoter activity was
determined by transient expression of the luciferase vectors in
MDA-MB-231 cells. In brief, 4 mg of the promoter vector was
mixed with 10 ml of Lipofetamine 2000 (Invitrogen, Carlsbad, CA)
and the mixture was slowly added to cells in a 6-well plate
(200,000 cells/well) and incubated for 24 h. The cells were then
washed, incubated in serum free medium for 24 h and treated
with quercetin for 24 h. Cells were lysed and luciferase activity was
measured using an assay kit (Promega, Madison, WI).
In vitro angiogenesis assay
HUVECs were used for angiogenesis assay according to a
previously described method [44]. HUVECs were grown in 100-
mm dishes until they were 80% confluent. The cells were
trypsinized, counted, and resuspended in serum-free medium at
a concentration of 4610
4 cells/ml. Six-well plates were evenly
coated with growth factor-reduced Matrigel (Becton Dickinson,
Milan, Italy), which was allowed to solidify at 37uC for 30 min
before endothelial cells were plated. Quercetin or vehicle control
was added together with angiogenic factors or cancer cell medium
to each well and incubated at 37uC for 4 h and 24 h. Tube
formation was quantified by counting the number of connected
cells in five randomly selected fields by using 2006magnification
and dividing that number by the total number of cells in the same
field.
DNA-protein binding by streptavidin-agarose pulldown
assay
Transactivator and p300 binding to a COX-2 core promoter
probes were determined by a streptavidin-agarose pulldown assay
as previously described [45,46]. This assay allows for simultaneous
quantitative determination of transactivators and coactivators that
complex with the DNA probes. A 478-bp biotin-labeled double-
stranded probe corresponding to COX-2 promoter sequence (230
to 2508) was synthesized. The sequence probe contains all the
sites required for COX-2 promoter activation. The binding assay
was performed by mixing 400 mg of nuclear extract proteins, 4 mg
of the biotinylated DNA probe and 40 ml of 4% streptavidin-
conjugated agarose beads at room temperature for 1 h in a
rotating shaker. Beads were pelleted by centrifugation to pull down
the DNA-protein complex. After washing, proteins in the complex
were analyzed by immunoblots using rabbit polyclonal antibodies
(1 mg/ml each) specific for the indicated transcription factors. A
nonrelevant biotinylated sequence 59-AGAGTGGTCACTACC-
CCCTCTG-39 was included as a non-specific control probe
(NSP). The mixture was incubated at room temperature for 1 h
with shaking, and centrifuged to pull down the DNA-protein
complex. DNA-bound transactivators or p300 were dissociated
and analyzed by Western blotting. A non-immune rabbit IgG
(1 mg/ml) was also used as negative controls.
Chromatin Immunoprecipitation (ChIP)
The ChIP assay was performed as previously described with
minor modifications (34). In brief, ,80% confluent cells were
serum-starved for 24 h and treated with or without quercetin at
37uC for 48 h. 1% formaldehyde was added to the culture
medium, and after incubation for 20 min at 37uC, the cells were
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lysis buffer (1% SDS, 10 mM Tris-HCl, pH 8.0,with 1 mM
phenylmethylsulfonyl fluoride, pepstatin A, and aprotinin) for
10 min at 4uC. The lysates were sonicated five times for 10 s each
time, and the debris was removed by centrifugation. One-third of
the lysate was used as DNA input control. The remaining two-
thirds of the lysate were diluted 10-fold with a dilution buffer
(0.01% SDS, 1% Triton X-100, 1 mM EDTA, 10 mM Tris-HCl,
pH 8.0, and 150 mM NaCl) followed by incubation with
antibodies against specific transactivators or a nonimmune rabbit
IgG control overnight at 4uC. Immunoprecipitated complexes
were collected by using protein A/G plus agarose beads. The
precipitates were extensively washed and incubated in an elution
buffer (1% SDS and 0.1 M NaHCO3) at room temperature for
20 min. Cross-linking of protein-DNA complexes was reversed at
65uC for 5 h, followed by treatment with 100 mg/ml proteinase K
for 3 h at 50uC. DNA was extracted three times with phenol/
chloroform and precipitated with ethanol. The pellets were
resuspended in TE buffer and subjected to PCR amplification
using specific COX-2 promoter primers (59 primer,
–709CTG-
TTGAAAGCAACTTAGCT
–690, and 39 primer
–32AGACT-
GAAAACCAAGCCCAT
–51
). The resulting product of 678 bp
for COX-2 in length was separated by agarose gel electrophoresis.
Analysis of HAT activity
Cells were transfected with a FLAG-p300 vector for 24 h and
treated with quercetin for 24 h. The nuclear extracts prepared
from the treated cells were immunoprecipitated with an anti-
FLAG M2 affinity gel (Sigma, St. Louis, MO). FLAG-p300 was
eluted with FLAG peptides and the HAT activity of the purified
FLAG-p300 was analyzed. FLAG-p300 were incubated for
30 min at 30uCi n1 0 0 ml HAT buffer (100 mM Tris HCl
pH 8, 20% glycerol, 2 mM DTT, 2 mM PMSF, 0.2 mM
EDTA, 0.1 M NaCl and 0.02 M butyric acid) containing
100 mg histone (Sigma, St. Louis, MO) and 35 pmol
3H-acetyl
Coenzyme A (Amersham, Piscataway, NJ). The samples were
spotted on P81 phosphocellulose squares (Upstate, Lake Placid,
NY) and [
3H] acetyl histone was measured in a scintillation
counter.
Acetylation analysis
Acetylation of p50 was determined as described previously (41).
Briefly, p50 in nuclear extracts was immunoprecipitated with a
specific antibody of p50 and the immunoprecipitate was pulled
down with protein A/G agarose beads (Santa Cruz Biotechnology,
Santa Cruz, CA). After extensive washing, p50 proteins were
separated in a 4–20% SDS-PAGE system and acetylated p50 was
detected with a monoclonal antibody against acetyl-lysine (1:1000
dilution) (Cell Signaling Tech., Beverly, MA).
Statistical analysis
Analysis of variance and Student’s t test were used to compare
the values of the test and control samples. P,0.05 was considered
to a statistically significant difference. StatView 5.0 (Abacus
Concepts, Inc., Berkeley, CA) and SAS software were used for
all statistical analyses. The significance was evaluated by the paired
t test. All the experiments were done three times, and mean values
and standard deviation were calculated.
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